Mesothelioma
Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 08/07/2021)
1ste line
BEAT (ETOP)
A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant pleural mesothelioma.
2nd line
Currently no open trials
1ste line
BEAT (ETOP)
A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant pleural mesothelioma.
2nd line
Currently no open trials